IMOVA : Phase IIa, randomized, open-label, parallel-group trial to evaluate the immunogenicity, safety, and tolerability of the Ervebo vaccine administered with Inmazeb in healthy adult volunteers.
- Funded by Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
- Total publications:0 publications
Grant number: ANRS0064s
Grant search
Key facts
Disease
EbolaStart & end year
20262027Known Financial Commitments (USD)
$705,000Funder
Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)Principal Investigator
Marie JaspardResearch Location
GuineaLead Research Institution
Service des maladies infectieuses et tropicale, Inserm UMR-1136 IPLESP Hôpital Saint-Antoine, Paris, FranceResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Phase 2 clinical trialSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IIBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
The ANRS0064s IMOVA project consists of the implementation of a phase IIa clinical trial to assess the impact of the effect, if any, of Inmazeb administration on neutralizing antibody responses induced by Ervebo Ebola Zaire vaccine. If an interaction is observed, this will determine the time interval required between administration of Inmazeb and the Ervebo vaccine.